# Simmons Foods

> Simmons Foods is a VC fund in Siloam Springs backing Medical and Agriculture. See 2 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Siloam Springs, United States
- Total investments: 2
- Last investment: Aug 2022
- Lead investor: 0%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/simmonsfoods/
- Website: https://simmonsfoods.com/
- Facebook: https://www.facebook.com/simmonsfoods/

Simmons Foods is a leading supplier of poultry, pet, and animal nutrition products. They believe in creativity before capital, and they can do that because they are privately owned and diversified. They offer food that includes pet food, prepared foods, and animal nutrition.

## Contacts

5 contacts available for Simmons Foods. Shizune tracks 2 team members at Simmons Foods. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/simmons-foods?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Medical | 1 | 50% |
| Agriculture | 1 | 50% |
| Health Care | 1 | 50% |
| Biotechnology | 1 | 50% |
| Meat and Poultry | 1 | 50% |

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 1 | 50% |
| Venture - Series Unknown | 1 | 50% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Bill Simmons | Founder | 0 | https://shizune.co/investors/profile/bill-simmons-9adb |
| David Jackson | Chief Operating Officer | 0 | https://shizune.co/investors/profile/david-jackson-bf2c |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Pacific GeneTech | Pacific GeneTech develops and commercializes first-in-class or best-in-class vaccines for areas of high unmet or underserved needs in food safety and livestock animal health. The global animal vaccine market is a valuable opportunity and is expected to reach US$20.6 billion by 2021. Livestock illness can lead to human infections, poor feedconversion, or loss of animals, making it a significant economic burden to producers.Founded in 2009, Pacific GeneTech focuses on developing and commercializing vaccines for the livestock industry through their proprietary Aegis platform which have broad cross-protection. In 2012, they acquired the exclusive global rights to Hercules Adjuvant Delivery System to enhance Aegis developed vaccines and explore partnership opportunities for other vaccine products. Pacific GeneTech has out-licensed two of its leading poultry vaccines addressing economically important gastro-intestinal pathogens and has out-licensed its Hercules adjuvant for use in third-party vaccines. Vaccines for other pathogens and animal species are under development. Pacific GeneTech is developing other applications for its Hercules adjuvant delivery system. Pacific GeneTech, through its affiliate company, PGTx, has commenced programs with collaborators addressing human dysentery. | $10M | Venture - Series Unknown | Aug 24, 2022 |  |
| Pacific GeneTech | Pacific GeneTech develops and commercializes first-in-class or best-in-class vaccines for areas of high unmet or underserved needs in food safety and livestock animal health. The global animal vaccine market is a valuable opportunity and is expected to reach US$20.6 billion by 2021. Livestock illness can lead to human infections, poor feedconversion, or loss of animals, making it a significant economic burden to producers.Founded in 2009, Pacific GeneTech focuses on developing and commercializing vaccines for the livestock industry through their proprietary Aegis platform which have broad cross-protection. In 2012, they acquired the exclusive global rights to Hercules Adjuvant Delivery System to enhance Aegis developed vaccines and explore partnership opportunities for other vaccine products. Pacific GeneTech has out-licensed two of its leading poultry vaccines addressing economically important gastro-intestinal pathogens and has out-licensed its Hercules adjuvant for use in third-party vaccines. Vaccines for other pathogens and animal species are under development. Pacific GeneTech is developing other applications for its Hercules adjuvant delivery system. Pacific GeneTech, through its affiliate company, PGTx, has commenced programs with collaborators addressing human dysentery. | $10M | Seed | Aug 24, 2022 |  |

2 of 2 investments shown.

## Co-investors
- [Arkansas Development Finance Authority](https://shizune.co/investors/profile/arkansas-development-finance-authority) — VC Fund, 2 deals together
- [FHB Ventures](https://shizune.co/investors/profile/fhb-ventures) — VC Fund, 2 deals together
- [PT Medion](https://shizune.co/investors/profile/pt-medion) — VC Fund, 2 deals together
- [Whist Subholdings](https://shizune.co/investors/profile/whist-subholdings) — VC Fund, 2 deals together

## Similar investors

### Similar industry
- [SVG Ventures](https://shizune.co/investors/profile/svg-ventures) — VC Fund
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [Omnivore](https://shizune.co/investors/profile/omnivore-partners) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

### Similar country
- [Alibaba Entrepreneurs Fund](https://shizune.co/investors/profile/alibaba-entrepreneurs-fund) — VC Fund
- [Animoca Brands](https://shizune.co/investors/profile/animoca-brands-corporation) — VC Fund
- [Gobi Partners](https://shizune.co/investors/profile/gobi-partners) — VC Fund

## Featured in investor lists
- [Medical Investors in Hong Kong](https://shizune.co/investors/medical-investors-hong-kong)
- [Medical VC Funds in Hong Kong](https://shizune.co/investors/medical-vc-funds-hong-kong)
- [Biotechnology Investors in Hong Kong](https://shizune.co/investors/biotechnology-investors-hong-kong)
- [Biotechnology VC Funds in Hong Kong](https://shizune.co/investors/biotechnology-vc-funds-hong-kong)
- [Health Care VC Funds in Hong Kong](https://shizune.co/investors/health-care-vc-funds-hong-kong)
- [Biotech VC Funds in Hong Kong](https://shizune.co/investors/biotech-vc-funds-hong-kong)

## FAQ

### What does Simmons Foods invest in?

Simmons Foods invests primarily in Medical, Agriculture and Health Care startups, most often at Seed and Venture - Series Unknown stage. Most of the 2 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Simmons Foods?

Public channels for Simmons Foods include LinkedIn, the website linked on this profile and Facebook. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Simmons Foods?

The team at Simmons Foods includes Bill Simmons (Founder) and David Jackson (Chief Operating Officer). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co